ClinicalTrials.gg
CompletedNCT07861529GP-LSGUpdated Oct 6, 2026

Effects of Posterior Gastropexy During Sleeve Gastrectomy on Quality of Life

An interventional study of Laparoscopic Sleeve Gastrectomy with Posterior Gastropexy and Standard Sleeve Gastrectomy in Obesity & Overweight, sponsored by Helwan University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Helwan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Mar 2023, registered Sep 2026).
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Obesity with a site in Egypt — 32 open to participants now, 39 under way, none of them phase 3. Obesity · Egypt.

Enrollment
70th of 102
50 · median 60
Started
2023
with 25 others
No phase
90 of 138
21 open now
Registered
135th of 138
by date

Among the 138 studies in Obesity with a site in Egypt, this one is the 70th largest by enrollment of the 102 interventional ones that give a count, is one of 26 that started in 2023, is one of 90 with no phase, and was the 135th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

32 of the 138 studies in Obesity with a site in Egypt are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Obesity with a site in Egypt, or all of them as a file.
02

Study summary

This randomized controlled trial evaluates the clinical outcomes and quality of life in patients undergoing laparoscopic sleeve gastrectomy with or without posterior gastropexy. The primary objective is to assess the effectiveness of posterior gastropexy in reducing postoperative reflux and improving overall patient satisfaction, with a 12-month follow-up period.

Read the detailed description

This study is designed as a pilot randomized controlled trial to investigate the role and clinical impact of adding posterior gastropexy to laparoscopic sleeve gastrectomy. Gastroesophageal reflux disease (GERD) is a frequent postoperative concern following sleeve gastrectomy; therefore, this trial aims to evaluate whether a posterior gastropexy technique can effectively mitigate postoperative reflux symptoms and enhance the patient's overall quality of life.

Eligible patients undergoing sleeve gastrectomy are randomly allocated into two groups: the study group receiving sleeve gastrectomy combined with posterior gastropexy, and the control group undergoing standard sleeve gastrectomy alone. Perioperative outcomes, intraoperative details, and postoperative complications are systematically documented. Patients are monitored through scheduled postoperative visits and standardized scoring questionnaires, including quality-of-life assessments (such as the GIQLI score), over a comprehensive 12-month follow-up period to assess both short- and medium-term clinical benefits.

03

Conditions studied

  • Obesity & Overweight

Keywords

  • obesity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 65 years scheduled for elective laparoscopic sleeve gastrectomy.
  • (BMI) of 35 kg/m² or greater.
  • Presence of preoperative symptoms or documentation of gastroesophageal reflux disease (GERD).
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • Previous history of bariatric or upper gastrointestinal surgery.
  • Large hiatal hernia requiring formal repair.
  • to general anesthesia or laparoscopy.
  • Pregnant or lactating females.Inclusion Criteria:
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Sleeve Gastrectomy with Posterior Gastropexy

    Patients undergo laparoscopic sleeve gastrectomy combined with posterior gastropexy technique.

    Procedure: Laparoscopic Sleeve Gastrectomy with Posterior Gastropexy

  • Active comparator
    Standard Sleeve Gastrectomy

    Patients undergo standard laparoscopic sleeve gastrectomy alone without posterior gastropexy.

    Procedure: Standard Sleeve Gastrectomy

Interventions

  • ProcedureLaparoscopic Sleeve Gastrectomy with Posterior Gastropexy

    Laparoscopic sleeve gastrectomy combined with posterior gastropexy to assess clinical outcomes and GERD reduction.

  • ProcedureStandard Sleeve Gastrectomy

    Standard laparoscopic sleeve gastrectomy procedure without posterior gastropexy.

06

What researchers measure

Primary outcomes

  1. Gastrointestinal Quality of Life

    Assessment of the GIQLI total score based on 36 items covering physical, emotional, and social functioning, along with gastrointestinal symptoms, scored from 0 to 144.

    Time frame: At 6 months and 1 year postoperatively

  2. Body Mass Index

    Measurement of the patient body mass index expressed in kilograms per meter squared (kg/m²).

    Time frame: At 6 months and 1 year postoperatively

07

Study locations

1 site
  • Helwan University
    Cairo, Cairo Governorate 11828, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — Yes, anonymized individual participant data will be made available upon reasonable request to the corresponding author.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Apr 2025, 25 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 25 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 6, 2026
StartActual
Mar 1, 2023
Primary completionActual
Apr 1, 2025
CompletionActual
Apr 1, 2025
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861529
Lead sponsor
Helwan University
Responsible party
Yasser Baz (ِAssociate Professor of general surgery, Helwan University) — Principal investigator
First posted
Oct 6, 2026
Start date
Mar 1, 2023
Primary completion
Apr 1, 2025
Completion
Apr 1, 2025
Last update
Oct 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion